Prime Therapeutics, Boehringer-Ingelheim Reach Outcomes-Based Contract for Jardiance
Empagliflozin (Jardiance) and another SGLT2 inhibitor, canagliflozin (Invokana) have been competing aggressively; both have clinical trial results showing cardiovascular benefits.
The pharmacy benefits manager (PBM) Prime Therapeutics, owned by 18 Blue Cross Blue Shield plans or subsidiaries, announced it will pay for the therapy empagliflozin (Jardiance) under an outcomes-based contract with Boehringer-Ingelheim. The companies announced the deal in a
Empagliflozin, first approved to treat type 2 diabetes (T2D), was the first such therapy found to have cardiovascular (CV) benefits and the first to have an FDA indication to reduce CV mortality. Since then, a competitor in the same class of sodium glucose co-transporter-2 (SGLT2) inhibitors, canagliflozin (Invokana) by Janssen, was also found to have CV benefits; the drug sponsor is also seeking a CV indication from FDA.
Competition between the 2 drugs is fierce. Going into 2018,
Two other SGLT2 inhibitors also have FDA approval: dapagliflozin (Farxiga) from AstraZeneca; and ertugliflozin (Steglatro) from Merck and Pfizer, which was approved along with combinations at the end of 2017.
“Because diabetes affects nearly 10% of the US population, Prime actively works to find solutions that can improve our members’ health outcome and control the overall costs of diabetes,” said Jonathan Gavras, MD, chief medical officer at Prime. He said the agreement would allow for the collection of key data beyond pharmacy claims and insights gained would “help drive the greatest value from the treatment.”
Alec Mahmood, chief financial officer at Prime, said the contract was one of several in recent months that sought to align incentives among payers, manufacturers, providers, and health plan members to make sure “drugs work as they are intended.”
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025
- Eating Behaviors May Predict GLP-1 Therapy Success in Type 2 Diabetes
September 18th 2025